EAM
VKTX icon

Exome Asset Management’s Viking Therapeutics VKTX Stock Holding History

Exome Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Buy
+47,861
New +$1.55M 1.15% 32

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Exome Asset Management's VKTX Position: Q2 2026 in Review

Exome Asset Management opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 47,861 shares worth $1.87M. The stake represents 1.15% of the portfolio and ranks #32 among its holdings.

432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Exome Asset Management held 47,861 shares of Viking Therapeutics worth $1.87M as of Q2 2026.
  • Viking Therapeutics was a new Exome Asset Management position in Q2 2026.
  • Viking Therapeutics made up 1.15% of Exome Asset Management's portfolio in Q2 2026, its #32 holding.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.